Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Functional luminal imaging probe

Published byΆιμον Γιαννόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Functional luminal imaging probe"— Presentation transcript:

1 Figure 4 Functional luminal imaging probe
study demonstrating decreased oesophagogastric junction distensibility Figure 4 | Functional luminal imaging probe study demonstrating decreased oesophagogastric junction distensibility. Oesophagogastric junction (EGJ) distensibility in this patient with achalasia is 1.3 mm2 per mmHg. The optimal threshold for detecting achalasia is <2.8 mm2 per mmHg. a | The positioning of the functional luminal imaging probe (FLIP) device at the EGJ along with the stepwise distension protocol. b | The corresponding FLIP display and calculated values for cross-sectional area, pressure and EGJ distensibility index are shown. CSA, cross-sectional area; FLIP, functional lumen impedance planimetry. Kahrilas, P. J. et al. (2017) Advances in the management of oesophageal motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 4 Functional luminal imaging probe"

Similar presentations

Figure 4 PET imaging in experimental pancreatic cancer

Figure 4 PET imaging in experimental pancreatic cancer
Figure 1 Proposed risk stratification for patients with NAFLD

Figure 1 Proposed risk stratification for patients with NAFLD
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 3 Low-grade inflammation in FGID

Figure 3 Low-grade inflammation in FGID
Figure 1 Imaging of a depressed intramucosal carcinoma

Figure 1 Imaging of a depressed intramucosal carcinoma
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 2 Approach to diagnosis and management of food allergy

Figure 2 Approach to diagnosis and management of food allergy
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Combination therapy for HCC

Figure 6 Combination therapy for HCC
Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Similar presentations

Ads by Google